Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 11/20 | 0.89 |
| ▸ | ALK | Q9UM73 | 11/20 | 0.89 |
| ▸ | EML4 | Q9HC35 | 10/20 | 0.89 |
| ▸ | RET | P07949 | 9/20 | 0.89 |
| ▸ | ROS1 | P08922 | 9/20 | 0.89 |
| ▸ | AXL | P30530 | 5/20 | 0.89 |
| ▸ | ETV6 | P41212 | 4/20 | 0.89 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.89 |
| ▸ | PLK4 | O00444 | 1/20 | 0.89 |
| ▸ | CIT | O14578 | 1/20 | 0.89 |
| ▸ | AURKA | O14965 | 1/20 | 0.89 |
| ▸ | GAK | O14976 | 1/20 | 0.89 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.89 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.89 |
| ▸ | BUB1 | O43683 | 1/20 | 0.89 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.89 |
| ▸ | STK16 | O75716 | 1/20 | 0.89 |
| ▸ | STK10 | O94804 | 1/20 | 0.89 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.89 |
| ▸ | LATS1 | O95835 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22652336 | 0.98 | FLT3 (0.89) | FLT3ALKEML4RETROS1 | |
| SCHEMBL328303 | 0.96 | FLT3 (0.94) | FLT3ALKEML4RETROS1 | |
| Gilteritinib SCHEMBL282229 | 0.94 | FLT3 (1.00) | FLT3ALKEML4RETROS1 | |
| Gilteritinib SCHEMBL29432551 | 0.94 | FLT3 (1.00) | FLT3ALKEML4RETROS1 | |
| Gilteritinib SCHEMBL29355822 | 0.94 | FLT3 (1.00) | FLT3ALKEML4RETROS1 | |
| SCHEMBL28655823 | 0.94 | FLT3 (0.88) | FLT3ALKEML4RETROS1 | |
| SCHEMBL29383062 | 0.94 | FLT3 (0.88) | FLT3ALKEML4RETROS1 | |
| SCHEMBL21455129 | 0.93 | FLT3 (0.82) | FLT3ALKEML4RETROS1 | |
| SCHEMBL10156928 | 0.92 | FLT3 (0.89) | FLT3ALKEML4RETROS1 | |
| SCHEMBL25483845 | 0.92 | FLT3 (0.86) | FLT3ALKEML4RETROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968234-B2 | Compound containing tricyclic heteroaryl group | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-20200354376-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2020-11-12 | — | — | US | disclosed |
| US-10730887-B2 | Compound containing tricyclic heteroaryl group | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2020-08-04 | — | — | US | disclosed |
| US-20190308993-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308993-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | JAK3, ERBB3, CDK3 | FLT3 19/4885ALK 5/4885EML4 2908/4885 |
| US-10968234-B2 | Compound containing tricyclic heteroaryl group | JAK3, ERBB3, CDK3 | FLT3 19/4885ALK 6/4885EML4 3070/4885 |
| US-20200354376-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | JAK3, ERBB3, CDK3 | FLT3 19/4885ALK 6/4885EML4 3070/4885 |
| US-10730887-B2 | Compound containing tricyclic heteroaryl group | JAK3, ERBB3, CDK3 | FLT3 19/4885ALK 5/4885EML4 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.